niacinamide has been researched along with Cells, Neoplasm Circulating in 17 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC)." | 9.17 | Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. ( Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM, 2013) |
| "We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect." | 9.17 | Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. ( Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH, 2013) |
| "To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)." | 7.88 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 7.83 | pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Chen, L; Ge, N; Li, J; Liu, H; Qian, H; Shi, L; Sun, B; Wu, M; Yang, X; Yang, Y; Yin, Z; Zhang, X, 2016) |
| "We evaluated the effect of sorafenib and intermittent hepatic arterial infusion chemotherapy (HAIC) using cisplatin for unresectable advanced hepatocellular carcinoma (HCC)." | 7.76 | [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y, 2010) |
| "Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein." | 6.73 | Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. ( Andreeff, M; Cortes, J; Estrov, Z; Harris, D; Konopleva, M; Ling, X; McQueen, T; Quintás-Cardama, A; Shi, YX; Small, D; Zhang, W, 2008) |
| "Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC)." | 5.17 | Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. ( Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM, 2013) |
| "We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect." | 5.17 | Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. ( Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH, 2013) |
| "To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)." | 3.88 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.83 | pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Chen, L; Ge, N; Li, J; Liu, H; Qian, H; Shi, L; Sun, B; Wu, M; Yang, X; Yang, Y; Yin, Z; Zhang, X, 2016) |
| "To evaluate the efficacy of transcatheter arterial chemoembolisation (TACE) compared with surgical intervention and sorafenib for treatment of hepatocellular carcinoma (HCC) in patients with tumor thrombus extending to the main portal vein." | 3.83 | Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. ( Bai, T; Chen, J; Chen, JZ; Li, LQ; Lu, Z; Ma, L; Peng, YC; Qin, HG; Xiang, BD; Xie, ZB; Ye, HH; Ye, JZ, 2016) |
| "Antiangiogenic therapy, specially sorafenib, has become the standard of care for patients with advanced hepatocellular carcinoma (HCC), however, the improvement in survival time is not satisfactory." | 3.79 | Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. ( Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY, 2013) |
| "We evaluated the effect of sorafenib and intermittent hepatic arterial infusion chemotherapy (HAIC) using cisplatin for unresectable advanced hepatocellular carcinoma (HCC)." | 3.76 | [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y, 2010) |
| "Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein." | 2.73 | Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. ( Andreeff, M; Cortes, J; Estrov, Z; Harris, D; Konopleva, M; Ling, X; McQueen, T; Quintás-Cardama, A; Shi, YX; Small, D; Zhang, W, 2008) |
| "Liver cancer has become the second cause of cancer-related death worldwide." | 2.52 | Liquid biopsy in liver cancer. ( Labgaa, I; Villanueva, A, 2015) |
| "A 71-year-old man with advanced left renal cell carcinoma (lymph node involvement and vena cava thrombus) was submitted to 6 months of neoadjuvant treatment with sorafenib before open radical nephrectomy." | 1.35 | Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. ( Andrea, A; Di Silverio, F; Panebianco, V; Parente, U; Passariello, R; Sciarra, A; Von Heland, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kodama, K | 1 |
| Kawaoka, T | 1 |
| Aikata, H | 1 |
| Uchikawa, S | 1 |
| Nishida, Y | 1 |
| Inagaki, Y | 1 |
| Hatooka, M | 1 |
| Morio, K | 1 |
| Nakahara, T | 1 |
| Murakami, E | 1 |
| Tsuge, M | 1 |
| Hiramatsu, A | 1 |
| Imamura, M | 1 |
| Kawakami, Y | 1 |
| Masaki, K | 1 |
| Honda, Y | 1 |
| Mori, N | 1 |
| Takaki, S | 1 |
| Tsuji, K | 1 |
| Kohno, H | 2 |
| Moriya, T | 1 |
| Nonaka, M | 1 |
| Hyogo, H | 1 |
| Aisaka, Y | 1 |
| Kimura, T | 1 |
| Nagata, Y | 1 |
| Chayama, K | 1 |
| Kelley, RK | 1 |
| Nimeiri, HS | 1 |
| Munster, PN | 1 |
| Vergo, MT | 1 |
| Huang, Y | 1 |
| Li, CM | 1 |
| Hwang, J | 1 |
| Mulcahy, MF | 1 |
| Yeh, BM | 1 |
| Kuhn, P | 1 |
| Luttgen, MS | 1 |
| Grabowsky, JA | 1 |
| Stucky-Marshall, L | 1 |
| Korn, WM | 1 |
| Ko, AH | 1 |
| Bergsland, EK | 1 |
| Benson, AB | 1 |
| Venook, AP | 1 |
| Zhu, XD | 1 |
| Sun, HC | 1 |
| Xu, HX | 1 |
| Kong, LQ | 1 |
| Chai, ZT | 1 |
| Lu, L | 1 |
| Zhang, JB | 1 |
| Gao, DM | 1 |
| Wang, WQ | 1 |
| Zhang, W | 2 |
| Zhuang, PY | 1 |
| Wu, WZ | 1 |
| Wang, L | 1 |
| Tang, ZY | 1 |
| Galanis, E | 1 |
| Anderson, SK | 1 |
| Lafky, JM | 1 |
| Uhm, JH | 1 |
| Giannini, C | 1 |
| Kumar, SK | 1 |
| Kimlinger, TK | 1 |
| Northfelt, DW | 1 |
| Flynn, PJ | 1 |
| Jaeckle, KA | 1 |
| Kaufmann, TJ | 1 |
| Buckner, JC | 1 |
| Garcia-Donas, J | 1 |
| Rodriguez-Antona, C | 1 |
| Jonasch, E | 1 |
| Kwon, T | 1 |
| Lee, JL | 1 |
| You, D | 1 |
| Jeong, IG | 1 |
| Song, C | 1 |
| Ahn, H | 1 |
| Kim, CS | 1 |
| Hong, JH | 1 |
| Suzuki, E | 1 |
| Ooka, Y | 1 |
| Chiba, T | 1 |
| Kobayashi, K | 1 |
| Kanogawa, N | 1 |
| Motoyama, T | 1 |
| Saito, T | 1 |
| Ogasawara, S | 1 |
| Tawada, A | 1 |
| Yokosuka, O | 1 |
| Labgaa, I | 1 |
| Villanueva, A | 1 |
| Li, J | 1 |
| Shi, L | 1 |
| Zhang, X | 1 |
| Sun, B | 1 |
| Yang, Y | 1 |
| Ge, N | 1 |
| Liu, H | 1 |
| Yang, X | 1 |
| Chen, L | 1 |
| Qian, H | 1 |
| Wu, M | 1 |
| Yin, Z | 1 |
| Ye, HH | 1 |
| Ye, JZ | 1 |
| Xie, ZB | 1 |
| Peng, YC | 1 |
| Chen, J | 1 |
| Ma, L | 1 |
| Bai, T | 1 |
| Chen, JZ | 1 |
| Lu, Z | 1 |
| Qin, HG | 1 |
| Xiang, BD | 1 |
| Li, LQ | 1 |
| Di Silverio, F | 1 |
| Sciarra, A | 1 |
| Parente, U | 1 |
| Andrea, A | 1 |
| Von Heland, M | 1 |
| Panebianco, V | 1 |
| Passariello, R | 1 |
| Hakenberg, OW | 1 |
| Shibuya, M | 1 |
| Novi, M | 1 |
| Lauritano, EC | 1 |
| Piscaglia, AC | 1 |
| Barbaro, B | 1 |
| Zocco, MA | 1 |
| Pompili, M | 1 |
| Gasbarrini, A | 1 |
| Ishizaki, M | 1 |
| Kaibori, M | 1 |
| Matsui, K | 1 |
| Yanagimoto, Y | 1 |
| Nakatake, R | 1 |
| Kwon, AH | 1 |
| Barbero, C | 1 |
| Salizzoni, S | 1 |
| Centofanti, P | 1 |
| Molino, F | 1 |
| Campisi, P | 1 |
| Giorgi, M | 1 |
| Rinaldi, M | 1 |
| Konopleva, M | 1 |
| Shi, YX | 1 |
| McQueen, T | 1 |
| Harris, D | 1 |
| Ling, X | 1 |
| Estrov, Z | 1 |
| Quintás-Cardama, A | 1 |
| Small, D | 1 |
| Cortes, J | 1 |
| Andreeff, M | 1 |
3 reviews available for niacinamide and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhy | 2013 |
Liquid biopsy in liver cancer.
Topics: Alleles; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; DNA, Neopla | 2015 |
Angiogenesis regulated by VEGF and its receptors and its clinical application.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2009 |
3 trials available for niacinamide and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tu | 2013 |
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Survival; Fluor | 2008 |
11 other studies available for niacinamide and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diph | 2013 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant | 2014 |
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; In | 2015 |
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; C | 2016 |
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherap | 2016 |
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemoth | 2008 |
Comment on Di Silverio et al.: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451-453.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; | 2008 |
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
Topics: Angiography; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Ad | 2009 |
[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc | 2010 |
Right sided heart mass reveals hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Live | 2012 |